These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37307082)

  • 1. Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry.
    Balbi GGM; Ahmadzadeh Y; Tektonidou MG; Pengo V; Sciascia S; Ugarte A; Belmont HM; Lopez-Pedrera C; Fortin PR; Wahl D; Gerosa M; de Jesús GR; Ji L; Atsumi T; Efthymiou M; Branch DW; Nalli C; Rodriguez Almaraz E; Petri M; Cervera R; Knight JS; Artim-Esen B; Willis R; Bertolaccini ML; Cohen H; Roubey R; Erkan D; de Andrade DCO;
    Rheumatology (Oxford); 2024 Mar; 63(3):772-779. PubMed ID: 37307082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository.
    Sevim E; Zisa D; Andrade D; Sciascia S; Pengo V; Tektonidou MG; Ugarte A; Gerosa M; Belmont HM; Zamorano MAA; Fortin PR; Ji L; Efthymiou M; Cohen H; Branch DW; de Jesus GR; Andreoli L; Petri M; Rodriguez E; Cervera R; Knight JS; Atsumi T; Willis R; Roubey R; Bertolaccini ML; Erkan D; Barbhaiya M;
    Arthritis Care Res (Hoboken); 2022 Feb; 74(2):324-335. PubMed ID: 32986935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study.
    Gkrouzman E; Willis R; Andrade D; Tektonidou MG; Pengo V; Ruiz-Irastorza G; Belmont HM; Fortin PR; Gerosa M; Signorelli F; Atsumi T; Branch DW; Nalli C; Rodriguez-Almaraz E; Petri MA; Cervera R; Knight JS; Efthymiou M; Cohen H; Bertolaccini ML; Erkan D; Roubey R;
    Lab Invest; 2023 Jun; 103(6):100147. PubMed ID: 37044248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies.
    Bala MM; Paszek E; Lesniak W; Wloch-Kopec D; Jasinska K; Undas A
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012534. PubMed ID: 30004572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in Antiphospholipid Antibody Profile between Patients with Obstetric and Thrombotic Antiphospholipid Syndrome.
    Anunciación-Llunell A; Muñoz C; Roggenbuck D; Frasca S; Pardos-Gea J; Esteve-Valverde E; Alijotas-Reig J; Miró-Mur F
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies.
    Vandevelde A; Chayoua W; de Laat B; Moore GW; Musiał J; Zuily S; Wahl D; Devreese KMJ
    J Thromb Haemost; 2022 Sep; 20(9):2136-2150. PubMed ID: 35713971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of IgA Antiphospholipid Antibodies Does not Improve Thrombotic Antiphospholipid Syndrome Classification: A two-Center Study.
    Su Z; Huang Z; Zhao J; Li M; Hu J; Zeng X; Hu C; Yang B
    Clin Appl Thromb Hemost; 2022; 28():10760296221081129. PubMed ID: 35379020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis.
    Sciascia S; Willis R; Pengo V; Krilis S; Andrade D; Tektonidou MG; Ugarte A; Chighizola C; Branch DW; Levy RA; Nalli C; Fortin PR; Petri M; Rodriguez E; Rodriguez-Pinto I; Atsumi T; Nascimento I; Rosa R; Banzato A; Erkan D; Cohen H; Efthymiou M; Mackie I; Bertolaccini ML;
    Thromb Res; 2019 Mar; 175():32-36. PubMed ID: 30685523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort.
    Radin M; Sciascia S; Erkan D; Pengo V; Tektonidou MG; Ugarte A; Meroni P; Ji L; Belmont HM; Cohen H; Ramires de Jesús G; Branch DW; Fortin PR; Andreoli L; Petri M; Rodriguez E; Rodriguez-Pinto I; Knight JS; Atsumi T; Willis R; Gonzalez E; Lopez-Pedrera R; Rossi Gandara AP; Borges Gualhardo Vendramini M; Banzato A; Sevim E; Barbhaiya M; Efthymiou M; Mackie I; Bertolaccini ML; Andrade D;
    Semin Arthritis Rheum; 2019 Dec; 49(3):464-468. PubMed ID: 31153708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry").
    Erton ZB; K Leaf R; de Andrade D; Clarke AE; Tektonidou MG; Pengo V; Sciascia S; Ugarte A; Belmont HM; Gerosa M; Fortin PR; Lopez-Pedrera C; Atsumi T; Zhang Z; Cohen H; Ramires de Jesús G; Branch DW; Wahl D; Andreoli L; Rodriguez-Almaraz E; Petri M; Barilaro G; Zuo Y; Artim-Esen B; Willis R; Quintana R; Vendramini MB; Barber MW; Bertolaccini ML; Roubey R; Erkan D
    Lupus; 2022 Dec; 31(14):1770-1776. PubMed ID: 36206383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional risk factors associated with thrombosis and pregnancy morbidity in a unique cohort of antiphospholipid antibody-positive patients.
    Li C; Zuo Y; Zhang S; Makris UE; Karp DR; Li Z
    Chin Med J (Engl); 2022 Mar; 135(6):658-664. PubMed ID: 35143425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.
    Mustonen P; Lehtonen KV; Javela K; Puurunen M
    Lupus; 2014 Dec; 23(14):1468-76. PubMed ID: 25164304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of antiphospholipid antibodies over time and its association with recurrence of clinical manifestations: A longitudinal study from a single centre.
    Barilaro G; Coloma-Bazan E; Chacur A; Della Rocca C; Perez-Isidro A; Ruiz-Ortiz E; Viñas O; Tàssies Penella D; Reverter JC; Molina Andujar A; Cervera R; Espinosa G
    Autoimmun Rev; 2022 Dec; 21(12):103208. PubMed ID: 36202304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is There an Additional Value in Detecting Anticardiolipin and Anti-β2 glycoprotein I IgA Antibodies in the Antiphospholipid Syndrome?
    Chayoua W; Yin DM; Kelchtermans H; Moore GW; Gris JC; Musiał J; Zuily S; Ten Cate H; de Laat B; Devreese KMJ
    Thromb Haemost; 2020 Nov; 120(11):1557-1568. PubMed ID: 32696448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of the detection of antibodies directed against domain 1 of β2-glycoprotein 1 in thrombotic antiphospholipid syndrome.
    Montalvão S; Elídio PS; da Silva Saraiva S; de Moraes Mazetto B; Colella MP; de Paula EV; Appenzeller S; Annichino-Bizzacchi J; Orsi FA
    Thromb Res; 2016 Dec; 148():32-37. PubMed ID: 27770664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up.
    Tarr T; Lakos G; Bhattoa HP; Soltesz P; Shoenfeld Y; Szegedi G; Kiss E
    Clin Rev Allergy Immunol; 2007 Apr; 32(2):131-7. PubMed ID: 17916982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombin generation assay and lupus anticoagulant synergically distinguish populations of patients with antiphospholipid antibodies.
    Radin M; Barinotti A; Cecchi I; Foddai SG; Rubini E; Roccatello D; Menegatti E; Sciascia S
    J Clin Pathol; 2023 Dec; 76(12):839-846. PubMed ID: 36100400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation.
    Forastiero R
    Lupus; 2014 Oct; 23(12):1252-4. PubMed ID: 25228718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository.
    de Azevedo Lopes E; Balbi GGM; Tektonidou MG; Pengo V; Sciascia S; Ugarte A; Belmont HM; Gerosa M; Fortin PR; Lopez-Pedrera C; Ji L; Cohen H; de Jesús GR; Branch DW; Nalli C; Petri M; Rodriguez E; Kello N; Ríos-Garcés R; Knight JS; Atsumi T; Willis R; Bertolaccini ML; Erkan D; Andrade D;
    Adv Rheumatol; 2021 Oct; 61(1):64. PubMed ID: 34711275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.
    Iwaniec T; Kaczor MP; Celińska-Löwenhoff M; Polański S; Musiał J
    Thromb Res; 2017 May; 153():90-94. PubMed ID: 28363116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.